These arms companies disqualify all products from the list and do not accept any purchase requests.

Recently, Heilongjiang Provincial Health Insurance Bureau issued the "Heilongjiang Province drug and medical supplies centralized procurement and price supervision and inspection measures (trial)" (hereinafter referred to as the "trial measures") shows that the implementation of medical supplies production and operation enterprises poor record dynamic management system and other pharmaceutical prices and credit evaluation system.
medical supplies production and operation enterprises have one of the following acts, included in the bad record and online publicity, cancel the enterprise's all products of the finalists, from the date of cancellation of two years, centralized procurement management institutions may not accept any of its products centralized procurement applications, the province's public medical institutions may not purchase their products in any form, the original signed purchase and sale contract terminated.
(1) determined by law enforcement and discipline authorities that there is commercial bribery in the purchase and sale of high-value medical supplies; (2) providing false and invalid documents; (3) making false and fraudulent attempts to defraud the finalists; (4) making malicious bids at prices below cost to disrupt market order; (5) raising prices or disguised prices on shortlisted varieties without authorization or disguised prices; (6) non-distribution or on-time distribution of shortlisted varieties, affecting clinical medical institutions; (7) After the medical institutions acceptance confirmation, the distribution of high-value medical supplies specifications, packaging and other information is inconsistent with the shortlisted varieties specifications, packaging and other information and do not agree to replacement; (8) to replace the shortlisted varieties with the finalists of high-value medical supplies for distribution; (9) violation of the existing medical device price management regulations; (10) malicious complaints, disrupt the normal order of centralized procurement; (11) centralized procurement management institutions.
it is understood that the "Trial Measures" are applicable to the centralized procurement and price behavior of drug market license holders, pharmaceutical production enterprises, pharmaceutical enterprises and medical supplies production and operation enterprises and public medical institutions within the jurisdiction of Heilongjiang Province. The Trial Measures for the
's maximum cancellation of five-year tender eligibility show that if a bidder participating in a bid for drug procurement bid bids bids at a lower price than the cost, or by means of fraud, bid rigging or abuse of market dominance, the competent medical security department of the people's government at or above the county level shall order it to correct and confiscate the illegal proceeds. If the winning bid is
, the winning bid shall be null and void, and the fine shall be imposed on the legal representative, the principal person in charge, the person in charge directly responsible and other responsible personnel shall be fined less than 5 percent of the amount of the unit and not less than 10 percent of the amount of the winning bid. If the
serious, he shall be disqualified from bidding for drug procurement within two to five years and shall be announced. At the same time,
, the relevant listing license holders, production enterprises, operating enterprises and their staff members involved in centralized procurement, if they provide false supporting documents or otherwise cheat, or take collusive quotations, price-fixing and other means to hinder fair competition, or by means of commercial bribery to engage in unfair competition to affect the centralized procurement work, etc., will be dealt with by the medical security department according to law. In addition, the Pilot Measures impose strict requirements on medical institutions,
. If the medical institution situated
and its staff involved in the centralized procurement of medicines commit any of the following acts, the medical security department shall, in accordance with law, deal with or transfer them to the relevant departments: (1) avoid the centralized procurement of drugs, purchase non-finalist drugs without authorization, or organize the purchase of medicines without prescribing the prescribed procedures; (2) provide false drug procurement information; (3) if the procurement of drugs is not signed in accordance with the provisions of the regulations Contract, or failure to pay back on time; (4) not to implement the price of centralized purchaseof drugs, to negotiate for secondary, disguised price, or to sign a supplementary clause and agreement with an enterprise that deviates from the substantive content of the contract; (5) to receive kickbacks or obtain improper benefits in the course of drug procurement, sale, use and return.
Annex: Measures for centralized procurement and price supervision and inspection of medicines and medical supplies in Heilongjiang Province (trial) Article 1 In order to further do a good job in the management of centralized procurement of medicines and medical supplies in public medical institutions in our province, regulate the conduct of public medical institutions and enterprises in the production and operation of pharmaceutical and medical supplies, according to the Basic Medical and Health Promotion Law of the People's Republic of China, the Price Law of the People's Republic of China, the Drug Administration Law of the People's Republic of China, the Measures for the Supervision and Administration of Drug Central Procurement (No. 6) Opinions on drug price management (Medical Insurance Issue (2019) No. 67), "High-value medical supplies centralized procurement norms (trial)" (2012) No. 86) relevant provisions, in accordance with the "National Medical Security Administration List of Administrative Law Enforcement Matters (2020 edition)" identified in the procurement of drugs and medical supplies and price management related administrative law enforcement matters, combined with the actual situation of our province, to formulate these measures. Article 2
The term "concentrated procurement" as mentioned in these Measures refers to the purchase of pharmaceutical and medical supplies on the centralized procurement platform for pharmaceuticaland medical supplies in accordance with relevant regulations by drug licensing holders, pharmaceutical production enterprises, pharmaceutical enterprises and medical supplies production and operation enterprises, and the procurement of medicines and medical supplies on the centralized procurement platform for pharmaceuticals and medical supplies in accordance with relevant provisions.
Article 3 These Measures shall apply to the centralized procurement and price behavior of drug market license holders, pharmaceutical production enterprises, pharmaceutical enterprises and medical supplies production and operation enterprises and public medical institutions within the jurisdiction of Heilongjiang Province.
Article 4 Medical security departments at all levels shall, in accordance with the principles of territorial administration and clear authority and responsibility, carry out centralized procurement of medicines and medical supplies and price supervision and management in accordance with the working functions of their respective departments.
Article 5 When engaged in the production, operation and use of pharmaceutical and medical supplies, laws, regulations, rules, standards and norms shall be observed to ensure that the information in the whole process is true, accurate, complete and traceable.
Article 6 Medical security departments at all levels shall strengthen the management and guidance of the procurement of drug classifications.
bidders participating in drug procurement tenders may not bid at below-cost bids, and may not bid by such means as fraud, bid rigging or abuse of market dominance.
Article 7 Medical security departments at all levels shall, in accordance with the provisions, carry out supervision and inspection of compliance with the centralized procurement of medicines in public medical institutions. Article 8
The supervision and inspection of compliance with the centralized procurement of drugs in public medical institutions mainly examines the following aspects: (1) the implementation of the relevant provisions on centralized procurement of medicines in medical institutions; (2) adherence to the principle of openness, fairness, fairness and "quality first and reasonable price"; (3) participation in centralized procurement of drugs and the use of shortlisted drugs in accordance with the contract; (4) the situation in which pharmaceutical production enterprises participate in bidding and fulfilling the procurement contract according to law.
Article 9 When performing their duties of supervision and management, medical security departments at all levels may, in accordance with the law, consult and copy relevant documents, materials, accounts, electronic information data, etc., and request relevant units or personnel to explain relevant issues, and request the assistance of the relevant functional departments or professional institutions. article 10
If a medical institution or its staff involved in the centralized procurement of drugs commits one of the following acts, the medical security department shall, in accordance with the law, deal with or transfer it to the relevant departments: (1) avoid the centralized procurement of drugs, purchase non-finalist drugs without authorization, or organize the purchase of medicines in accordance with the prescribed procedures; (2) provide false drug procurement information; (3) if the procurement contract is not signed in accordance with the provisions; Or not to pay back the money on time; (4) not to implement the price of the centralized purchase of drugs, the secondary bargaining, disguised price pressure, or to sign the supplementary terms and agreements with the enterprise that deviate from the substantive content of the contract; (5) to receive kickbacks or obtain improper benefits in the course of drug procurement, sale, use and withdrawal; and (6) other illegal and illegal acts.
Article 11 If a medical institution violates these Measures, it shall order it to correct the error and inform the criticism, and if the circumstances are serious, the relevant leaders and those responsible shall be held accountable in accordance with the law. If a
medical personnel violate these Measures, they shall, in accordance with the relevant provisions, give critical education, organize and handle, discipline and discipline of the Party, and transfer them to the judicial organs for handling if they are suspected of committing a crime. article 12
If the holder of a drug market license, a pharmaceutical production enterprise, a pharmaceutical enterprise or its staff involved in the centralized procurement of drugs commits one of the following acts, the medical security department shall deal with it according to law: (1) providing false supporting documents or otherwise falsifying; (2) using collusive quotations, price-fixing and other means to obstruct fair competition, or engaging in unfair competition by commercial bribery to affect centralized procurement work (3) After the publication of the drug procurement variety, not for force majeure withdrawal or refusal to sign a procurement contract with medical institutions; (4) unauthorized price increase selling or disguised price increases during the procurement cycle; (5) unauthorized distribution of non-finalist drugs, non-distribution of drugs as stipulated in the contract, or distribution in violation of the relevant provisions; (6) other illegal and illegal acts.
Article 13 If the holder of a drug listing license, a pharmaceutical production enterprise, a pharmaceutical enterprise and its staff violate these Measures, the medical security department shall deal with the drug price and the credit evaluation system for recruitment in the field of pharmaceutical products and medical supplies in Heilongjiang Province, and if the crime is suspected to be transferred to the judicial organ for handling. article 14
Where a bidder participating in a tender for the procurement of drugs bids bids at a price below cost, or by way of fraud, bid rigging or abuse of market dominance, the competent department of medical security of the people's government at or above the county level shall order it to correct and confiscate the illegal proceeds; Fines of up to 10 per thousand above shall be fined not less than 5 percent of the amount of the unit and 10 percent of the amount of the fine imposed by the legal representative, the principal person in charge, the person in charge directly responsible and other responsible persons;
Article 15 Medical security departments at all levels shall, in accordance with the provisions, supervise and inspect compliance with the centralized procurement of high-value medical supplies in public medical institutions.
Article 16 Medical security departments at all levels shall set up whistle-blowing telephones, open e-mail addresses, etc. and publish them to the public, so that medical institutions, medical supplies production and operation enterprises and the public shall supervise the performance of their duties by relevant personnel. Article 17
The medical security departments at all levels mainly supervise and manage the following aspects: (1) the implementation of relevant laws and regulations; (2) the organization and implementation of procurement methods and procurement procedures; (3) information disclosure of procurement information; (4) the construction of the procurement system; (5) inquiries and questioning of the handling of the situation; (6) the establishment and improvement of the management mechanism for centralized procurement bad records; and (7) other situations that need to be monitored and managed. article 18
The implementation of medical supplies production and operation enterprises poor record dynamic management system and other pharmaceutical prices and recruitment credit evaluation system.
medical supplies production and operation enterprises have one of the following acts, included in the bad record and online publicity, cancel the enterprise's all products of the finalists, from the date of cancellation of two years, centralized procurement management institutions may not accept any of its products centralized procurement applications, the province's public medical institutions may not purchase their products in any form, the original signed purchase and sale contract terminated.
(1) determined by law enforcement and discipline authorities that there is commercial bribery in the purchase and sale of high-value medical supplies; (2) providing false and invalid documents; (3) making false and fraudulent attempts to defraud the finalists; (4) making malicious bids at prices below cost to disrupt market order; (5) raising prices or disguised prices on shortlisted varieties without authorization or disguised prices; (6) non-distribution or on-time distribution of shortlisted varieties, affecting clinical medical institutions; (7) After the medical institutions acceptance confirmation, the distribution of high-value medical supplies specifications, packaging and other information is inconsistent with the shortlisted varieties specifications, packaging and other information and do not agree to replacement; (8) to replace the shortlisted varieties with the finalists of high-value medical supplies for distribution; (9) violation of the existing medical device price management regulations; (10) malicious complaints, disrupt the normal order of centralized procurement; (11) centralized procurement management institutions. article 19
If a medical institution and its staff involved in centralized procurement have one of the following acts, the competent leadership shall be investigated according to the circumstances, in addition to the parties concerned. if
suspected of committing a crime, it shall be handed over to the judicial organ for handling in accordance with the law.
(1) not participating in centralized procurement activities of high-value medical supplies and circumventing centralized procurement activities in any other way; (2) providing false historical information on the procurement of high-value medical supplies; (3) not signing a purchase and sale contract with a medical supplies production and operation enterprise in accordance with the provisions; (4) not purchasing the finalists in accordance with the purchase and sale contract, and purchasing the high value of the non-finalists without authorization Medical supplies replace the shortlisted varieties, fail to settle the purchase price on time or other acts of non-performance of contractual obligations; (5) after the signing of the contract for the purchase and sale of high-value medical supplies, and then conclude with the enterprise other agreements that deviate from the substantive content of the contract to obtain other improper benefits; (6) accept the money or other benefits of the production and operation of medical supplies enterprises; (7) other acts that violate laws and regulations.
Article 20 For drugs that are market-adjusted in accordance with the law, the holders of drug market licenses, pharmaceutical production enterprises, drug-operating enterprises and medical institutions shall set prices in accordance with the principles of fairness, reasonableness and good faith and consistent quality prices, and provide drug users with reasonably priced drugs.
Article 21 Drug market licensing holders, drug production enterprises, drug-operating enterprises and medical institutions shall abide by the provisions of the competent department of drug prices under the State Council on drug price management, formulate and mark the retail price of drugs, and prohibit acts such as windfall profits, price monopoly and price fraud.
Article 22 The State shall establish and improve a system of drug price monitoring, monitor drug prices, conduct cost price investigations, strengthen drug price supervision and inspection, investigate and punish illegal acts of price monopoly and price hikes, and maintain the order of drug prices in accordance with the law.
Article 23 Medical security departments at all levels shall, in accordance with law, carry out supervision and inspection of drug licensing holders, drug production enterprises, drug-operating enterprises and medical institutions that provide the competent departments of drug prices with information on the actual purchase and sale price selling prices and quantities of their drugs.
Article 24 The holders of drug listing licenses, drug manufacturers, pharmaceutical enterprises and medical institutions shall, in accordance with law, provide the competent department selling and selling of their drugs with information such as the actual purchase price and quantity of their drugs.
include books, documents, vouchers, documents and other information related to their business practices.
Article 25 The medical security departments at all levels may require the holders of drug market licenses, pharmaceutical manufacturers and pharmaceutical enterprises to provide information on production, operation, finance and product flow related to the composition of the price of drugs.
(1) drugs with price increases or unusual frequency in their jurisdiction; (2) drugs with large price differences between regions or between online and offline;